Where they once had to rely on a limited view of a patient and their disease, researchers increasingly have access to detailed datasets from individual patients and thousands of similar patients — often collected during routine clinical care. This type of data opens up new avenues of research, and can possibly reveal new or improved treatments.
Roche has always focused on translating scientific discovery into novel medicines, biomarkers and diagnostics to advance personalised medicine. Now, with a greater volume and diversity of health data available than ever before, our researchers can achieve unique insights faster, and potentially develop more options for people with conditions that don’t respond to existing therapies.
Genomic profiling: A laboratory method that we use to understand the DNA associated with tumor cells, and the genetic mutations that may be specific to that cancer.
Through our collaborations with Flatiron Health and Foundation Medicine, a real-world, de-identified clinico-genomic database is enabling us to probe these types of questions at an unprecedented scale, and could accelerate drug discovery.